At the end of the day, any company interested in making 10's of billions of dollars will be interested in acquiring Amarin on the back of that R-IT data. The company that ultimately buys Amarin (if it is indeed sold) will have plenty of knowledge in the area of cardiovascular medicine, and deep pockets.
Pfizer, Merck, Amgen, and AZN are the frontrunners for me, and if there was ever going to be a bidding war for a company then surely this is the one.
If this goes to the 20s within the next couple of weeks and there isn't an offer made, GIA then becomes the reality for me, and I wouldn't expect any BO offers until around the same time next year -once the sNDA has been approved.
It's 15-20B now with CVRs for me, or 40B+ with CVRs after sNDA approval, or a 50B+ market cap several years from now with GIA.
News 
Market Data 
Discover 
